Background: The diagnosis of inborn errors of purine and pyrimidine metabolism is often difficult. We examined the potential of 1 H-NMR as a tool in evaluation of patients with these disorders.
data points per scan; sweep width, 6605 Hz). For urine samples, only minimal sample preparation was required. Derivatization, extraction, and deproteinization were not necessary. The pH of each sample was adjusted with a minimal volume of HCl to pH 2.50 Ϯ 0.05.
For quantification, trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP; sodium salt) was added as internal standard in a final concentration of 2.02 mmol/L (50 L of TSP in D 2 O into 500 L of urine). The sample volume in the NMR spectrometer was standardized at 500 L. The water resonance was presaturated during the relaxation delay (6 s) . For shimming of the magnetic field, the 29 Si-1 H long-range coupling of 3 Hz in the TSP resonance was used.
For data analysis, a Sine-Bell squared filter (SBB ϭ 2) was used. Spectra were Fourier transformed after the free induction decay was zero-filled to 65 536 data points. The phase and baseline of the spectra were corrected manually. Resonances were fitted semi-automatically to a Lorentzian line shape model function. Integrals of these fits were used for metabolite quantification. Metabolites in urine are expressed per millimole of creatinine. For analysis of the spectra, 1D WinNMR and WinFit software were used (Bruker Analytische Messtechnik).
When certain compounds are described in this study as "NMR invisible", it means that in the relevant concentration range no characteristic signals could be observed under the 1 H-NMR spectroscopy standard operating conditions used. The detection limit of 1 H-NMR spectroscopy for each metabolite depends on the number of protons that contribute to a signal and on the multiplicity of the resonance (5, 7 ) . When the molecule contains a methyl group, the estimated detection limit is in the range between 5 mol/L for a singlet resonance and 10 mol/L for a doublet resonance. Some purines and pyrimidines have only one proton contributing to the signal. The estimated detection limit of the technique in such a case is 15 mol/L for a singlet resonance and 30 mol/L for a doublet resonance. Some metabolites have no contributing proton in their chemical structure. For this reason, metabolites such as uric acid and 2,8-dihydroxyadenine are NMR invisible. It is conceivable that uric acid can be detected by 1 H-NMR spectroscopy under different experimental conditions (e.g., at a different pH). Obviously, this Enzymes involved are: adenylosuccinate lyase (1), ADA (2), PNP (3), XDH (4), HGPRT (5) , APRT (6) , dihydropyrimidine dehydrogenase (7) , dihydropyrimidinase (8) , and ␤-ureidopropionase (9) . PRPP, 5-phospho-␣-D-ribosyl-1-pyrophosphate; SAICAR, SAICA-ribotide; AICAR, aminoimidazole carboxamide ribotide; FAICAR, formylaminoimidazole carboxamide ribotide; S-AMP, adenylosuccinate; S-adenosine, succinyladenosine.
would be of utmost importance for diagnosing purine inborn errors. However, because such conditions are likely to introduce other problems in the interpretation of the NMR spectra, the standard operating procedure that we have used for a long time in diagnosing inborn errors of metabolism was also used in the present study.
Model compounds used in this study are available from Sigma Chemical Co., except for 5-acetyl-amino-6formyl-amino-3-methyl uracil (kindly provided by Prof. H.A. Simmonds, Guy's Hospital, London, UK) and succinylaminoimidazole carboxamide (SAICA)-riboside and succinyladenosine (kindly provided by Prof. G. van den Berghe, Université Catholique de Louvain, Brussels, Belgium).
The diagnoses of all patients used in this study originally were made in the period 1981-1998 at various metabolic screening laboratories in The Netherlands, Germany, and Belgium. Samples were stored at Ϫ20 or Ϫ80°C until analysis. These laboratories all used standard HPLC techniques (reversed-phase column, quantification by reading the absorbance at 260 nm) for measurement of purines and pyrimidines in body fluids.
Results

quantitative performance of nmr spectroscopy
The quantitative data found with NMR spectroscopy are compared with the HPLC results for relevant metabolites in Table 1 . The HPLC results are the quantitative data on the sample that were available from the laboratory that originally diagnosed the patient. For some samples, this means that Ͼ10 years may have elapsed between the HPLC and NMR measurements. Unfortunately, the limited volumes of most of the samples made repeating the HPLC measurement simultaneously with NMR spectroscopy impossible. The results of both techniques compare rather well for most of the metabolites, although rather large discrepancies were observed for uracil, thymine, inosine, deoxyinosine, and deoxyguanosine.
interpretation of the 1 h-nmr spectrum
It is advantageous that many of the relevant compounds in purine and pyrimidine metabolism have a chemical shift between 5.5 and 9.0 ppm, a region of the spectrum where only few metabolites present in body fluids have resonances. Other known metabolites in this part of the spectrum are tyrosine, phenylalanine, formic acid, indoxyl sulfate, histidine, and hippuric acid. A list of 1 H-NMR the resonances of these compounds is available (5, 7 ) . Table 2 shows the resonances of the purine and pyrimidine metabolites that are relevant under nondiseased physiological conditions or in patients with inborn errors of metabolism in these pathways. The most important resonances of a molecule for its identification in the 1 H-NMR spectrum have been listed in Table 2 . Some molecules have only one resonance, whereas others posses multiple resonances. These can be recognized by their complete "fingerprints" in the spectrum.
Generally there is only minimal intersample variation in the chemical shift of a certain resonance (Ͻ0.005 ppm), which allows reliable identification of the various purines and pyrimidines in urine, plasma, and CSF. The only exception was the extremely variable chemical shift of the singlet resonance from the proton on carbon-2 of the imidazole ring of SAICA-riboside, which varied between 8.05 and 8.26 ppm between samples. The SAICA-riboside doublet resonance at 5.77 ppm has a stable resonance position, thus allowing reliable identification of this metabolite.
inborn errors of pyrimidine metabolism
Dihydropyrimidine dehydrogenase (EC 1.3.1.2) deficiency. Dihydropyrimidine dehydrogenase is the initial enzymatic step in the degradative pathway of the pyrimidine bases uracil and thymine (Fig. 1B) . The enzyme converts both compounds into their respective 5,6-dihydro derivatives. 1 H-NMR spectra were obtained from urine samples of four unrelated cases with dihydropyrimidine dehydroge- nase deficiency. An example of a 1 H-NMR spectrum of a urine sample of one of these cases has been published previously (12 ) . In all samples, uracil and thymine were clearly increased (uracil, 95-626 mol/mmol creatinine; thymine, 270 -470 mol/mmol creatinine). In nondiseased urine samples, thymine cannot be detected with NMR spectroscopy, whereas uracil is observed in trace amounts in some samples (Ͻ10 mol/mmol creatinine). 5-Hydroxymethyluracil, a metabolite of thymine, was not detectable in the samples.
Dihydropyrimidinase (EC 3.5.2.2) deficiency. Dihydropyrimidinase (5,6-dihydropyrimidine amidohydrolase) is the second enzyme in the breakdown of the pyrimidine bases uracil and thymine. It catalyzes the conversion of 5,6dihydrouracil to 3-ureidopropionic acid and of 5,6-dihydrothymine to 3-ureidoisobutyric acid ( Fig. 1B) . To our knowledge, only seven cases of this enzyme defect have been described. We measured urine, plasma, and CSF in three patients with this defect. Two of these patients have been described clinically [case 1 by Putman et al. (9 ) ; case 2 by Assmann et al. (10 ) ], whereas case 3 was diagnosed recently. Examples of 1 H-NMR spectra of urine and CSF of these patients have been published previously (9, 10 ) and, therefore, are not shown here. Diagnostically high concentrations of uracil, thymine, and dihydropyrimidines were found with 1 H-NMR spectroscopy in the urine of all three patients (concentrations of uracil, thymine, 5,6-dihydrouracil, and 5,6-dihydrothymine: 9 -144, 44 -230, 178 -760, and 132-490 mol/mmol creatinine, respectively). The CSF of cases 1 and 2 showed obviously increased concentrations for the dihydropyrimidines, but only slightly increased concentrations for uracil and thymine (concentrations of uracil, thymine, 5,6-dihydrouracil, and 5,6-dihydrothymine: not detectable, trace to 10 mol/L, 46 -117 mol/L, and 79 -179 mol/L, respectively). The CSF of the third patient was not available. For all four compounds, the concentrations in plasma were obviously lower than in CSF (9 ) . The absence of high concentrations of 3-ureidopropionic acid (N-carbamyl-␤alanine; model compound, Sigma cat. no. C3750) in the urine or CSF of these patients excluded ␤-ureidopropionase deficiency as a possible defect. NMR findings were compatible with dihydropyrimidinase deficiency, which was later confirmed enzymatically in the liver of cases 1 and 2 (10, 13, 14 ) . A liver biopsy of case 3 was not available.
␤-Ureidopropionase (EC 3.5.1.6) deficiency. ␤-Ureidopropionase catalyzes two reactions: the conversion of 3-ureidopropionic acid and 3-ureidoisobutyric acid into ␤-alanine and 3-aminoisobutyric acid, respectively. A deficiency of the enzyme has not yet been recognized in humans. However, resonances of both substrates should be visible in the 1 H-NMR spectra of body fluids of a patient with this defect. Table 2 gives the characteristic resonances of 3-ureidopropionic acid. HGPRT also is a purine salvage enzyme, converting hypoxanthine and guanine into IMP and GMP, respectively ( Fig. 1A ). In the deficiency state, guanine and hypoxanthine are instead converted into xanthine and finally into uric acid. Uric acid overproduction is a characteristic of Lesch-Nyhan disease. Uric acid is a trioxypurine without protons on its carbon atoms; therefore, it is 1 H-NMR invisible. Increased hypoxanthine and xanthine are expected to be the only characteristic abnormalities in the NMR spectrum in body fluids of untreated Lesch-Nyhan patients. Urine samples of three classical Lesch-Nyhan cases were measured. Two of these patients were on allopurinol medication. In the 1 H-NMR spectrum of the patient without allopurinol, xanthine and hypoxanthine were clearly increased (xanthine, 37 mol/mmol creatinine; hypoxanthine, 198 mol/mmol creatinine; reference values for both compounds, Ͻ4.1 mol/mmol creatinine). In other cases of Lesch-Nyhan disease, xanthine in urine may be within the reference interval, but hypoxanthine will always be increased. In the patients that used medication, the excretion was higher (xanthine, 312-827 mol/mmol creatinine; hypoxanthine, 855-1363 mol/mmol creatinine) because feedback inhibition of de novo purine synthesis by IMP and GMP does not take place because of the HGPRT deficiency. Guanine was not detectable, whereas orotidine was clearly increased in both samples (112 and 63 mol/mmol creatinine). This can be explained by the inhibitory effect of oxypurinol, which is generated from allopurinol by the enzymatic action of XDH or aldehyde oxidase (AO; Fig. 2 ) on orotate phosphoribosyl transferase. Resonances from allopurinol-1-ribonucleotide and allopurinol-1-riboside were not observed because the conversion of allopurinol into these metabolites requires the action of HGPRT, which is deficient in these patients (Fig.  2) . In the CSF of the untreated patient, xanthine and hypoxanthine were both increased (22 and 94 mol/L respectively). In most CSF samples, both compounds are not observed in the NMR spectrum because the reference intervals for both are below the detection limit of the technique under the conditions used.
Adenosine deaminase (ADA; EC 3.5.4.4) deficiency. ADA catalyzes the conversion of adenosine into inosine. The enzyme also accepts deoxyadenosine as a substrate, converting it to deoxyinosine (Fig. 1A) . Deoxyadenosine and adenosine therefore are the metabolites that are of diagnostic importance. In urine, deoxyadenosine generally is present in higher concentrations than adenosine in patients with ADA deficiency. We investigated the urine of one patient with this disease. The NMR spectrum showed the presence of high concentrations of deoxyadenosine (205 mol/mmol creatinine; reference value, Ͻ1 mol/ mmol creatinine). Adenosine was not detectable with NMR spectroscopy, but was within the reference interval when the sample was analyzed with HPLC. Orotic acid was not observed in the NMR spectrum. A complication in the NMR spectrum was the presence of an unknown doublet resonance at 6.54 ppm, which interfered with the 6.54 triplet resonance from deoxyadenosine. Determining whether the doublet resonance is a characteristic feature for this metabolic defect requires measurement of additional samples from ADA-deficient cases.
Purine-nucleoside phosphorylase (PNP; EC 2.4.2.1) deficiency. PNP catalyzes the reversible phosphorylation of inosine and deoxyinosine or guanosine and deoxyguanosine to give either hypoxanthine or guanine plus the corresponding ribose-1-phosphate ( Fig. 1A) . Therefore, inosine, guanosine, and their deoxy forms are increased in body fluids in the PNP-deficient state. Fig. 3A shows the 1 H-NMR spectrum of a urine of a patient with this deficiency. Urine samples from two cases were available. Both patients had the typical clinical signs and symptoms of PNP deficiency (15, 16 ) . The enzyme defect was shown in erythrocytes and fibroblasts in both cases. We found increased concentrations for inosine (case 1, 49 mol/ mmol creatinine; case 2, 1110 mol/mmol creatinine), guanosine (case 1, 35 mol/mmol creatinine; case 2, 588 mol/mmol creatinine) and deoxyinosine [case 1, trace (Ͻ5 mol/mmol creatinine); case 2, 522 mol/mmol creatinine]. In controls, these compounds are found in the urine in very low concentrations (Ͻ1 mol/mmol creatinine). Deoxyguanosine was not observed in the urine of case 1, but could clearly be observed in the urine of case 2 (322 mol/mmol creatinine; reference, Ͻ1 mol/mmol creatinine). Xanthosine was not found in the urine samples of the two patients. The metabolite concentrations between the two patients showed remarkable differences.
In addition, other differences between the patients were observed. Increased orotic acid (95 mol/mmol creatinine; reference, Ͻ10 mol/mmol creatinine) was observed in case 1, but not in case 2. Orotidine was not detectable in these samples. The patients had not used allopurinol medication. Very high, as yet unexplained, resonances (doublet resonances at 5.33 and 5.40 ppm and singlet resonances at 5.60, 5.63, 6.08, and 6.63 ppm) were found in the sample of case 1. In case 2, the 5.40 ppm doublet resonance and the 6.63 ppm singlet resonance were also observed, although these resonances were considerably lower than in the urine of case 1. The 6.08 ppm resonance may be present in the urine of case 2, but this resonance would overlap with the doublet resonance deriving from the very high concentration of inosine in this sample. The urine sample of case 2 contained very high additional unknown resonances (singlet resonance at 2.26 ppm and doublet resonance at 2.96 ppm) that were not present in the urine of case 1. A plasma sample from another patient had clearly increased inosine (case 3, 40 mol/L; reference, Ͻ0.1 mol/L), whereas guanosine and both deoxy compounds were not detectable. Except for the 6.08 ppm singlet resonance, the other unknowns observed in the urine of the other two patients were not detectable in this blood sample. It would require measurement of urine samples from other patients with this defect to determine whether these unknown resonances are caused by the metabolic block.
Xanthinuria. In classical xanthinuria, a deficiency of XDH (EC 1.1.1.204) exists. The enzyme converts hypoxanthine into xanthine and xanthine into uric acid (Fig. 1A) . Furthermore, a combined XDH/AO deficiency is known. Patients with the combined defect have an inability to convert allopurinol to oxypurinol (Fig. 2) . In both diseases, xanthine is the predominant purine excreted. Urine samples of three patients from two families with isolated XDH deficiency could be measured both before and during allopurinol therapy. In one patient, isolated XDH deficiency was confirmed enzymatically. In urines from three patients not on medication, the increased xanthine concentration was the only characteristic feature in the 1 H-NMR spectrum (154 -890 mol/mmol creatinine; Fig.  3B ), and hypoxanthine was slightly increased (37-217 mol/mmol creatinine). In four additional urine samples of two of these patients while on allopurinol treatment, a similar picture was observed. The xanthine concentrations tended to be even higher than before treatment (507-941 mol/mmol creatinine). This may relate to the competitive inhibition of oxypurinol deriving from allopurinol on the residual XDH activity. Resonances from allopurinol (14 -1176 mol/mmol creatinine) and oxypurinol (255-367 mol/mmol creatinine) were observed in the 1 H-NMR spectrum of these four samples (Fig. 3B) .
The presence of oxypurinol illustrates that the patients have isolated XDH deficiency because oxypurinol cannot be formed in the combined XDH/AO deficiency because this requires AO enzymatic activity (Fig. 2) . Allopurinol-1-riboside could also be detected (31-161 mol/mmol creatinine). In the urine of one patient while on allopurinol, the orotidine concentration was 30 mol/mmol creatinine. We were unable to demonstrate the presence of oxypurinol-1-riboside or oxypurinol-7-riboside while the patients were on allopurinol. Their detection with 1 H-NMR spectroscopy is hampered by the fact that they are not available as model compounds.
Molybdenum cofactor deficiency. Patients with molybdenum cofactor deficiency have an inability to synthesize the pteridyl moiety of the cofactor essential for the enzymatic activity of XDH, sulfite oxidase, and AO. Xanthinuria, hypouricemia, and increased urinary sulfite, S-sulfocysteine, and thiosulfate concentrations are characteristic for the disease. Xanthinuria can be demonstrated easily in the 1 H-NMR spectrum. Serum and CSF samples were available from one patient with this defect. Xanthine was increased in both body fluids (case 1: serum xanthine, 136 mol/L; CSF xanthine, 24 mol/L). Hypoxanthine was not clearly increased in these samples. Urine was available of four patients with this defect (cases 2-5). In three of these patients without medication (cases 2-4), xanthine was clearly increased (450 -498 mol/mmol creatinine), whereas hypoxanthine was only slightly increased (47-56 mol/mmol creatinine). Xanthosine was detected in only one of these urine samples, in a low concentration (80 mol/mmol creatinine). An additional patient (case 5) described by van Gennip et al. (17 ) was on allopurinol treatment because of the existence of renal xanthine stones. In this case, clearly increased xanthine was found in three urine samples during allopurinol treatment (xanthine, 275-726 mol/mmol creatinine), whereas hypoxanthine was only slightly increased (22-67 mol/mmol creatinine). Allopurinol was found in two of the three samples, whereas all three samples contained allopurinol-1-riboside (314 -834 mol/mmol creatinine). No oxypurinol was found because allopurinol cannot be converted into oxypurinol in this disease (Fig. 2) . Sulfite and thiosulfate are 1 H-NMR invisible, and S-sulfocysteine could not be demonstrated in any of the urines of the patients with molybdenum cofactor deficiency. For S-sulfocysteine, this may relate to its instability under certain pH conditions or to the fact that NMR spectroscopy under the conditions used is too insensitive for its detection. This relative insensitivity is caused by the multiplicity of the resonance (4.26 doublet-doublet resonance, four peaks) and by the fact that only one proton contributes to this signal. Orotidine was not increased in any of these samples, as expected.
Adenylosuccinate lyase (EC 4.3.2.2) deficiency. Adenylosuccinate lyase, or adenylosuccinase, catalyzes two reactions in the biosynthesis of purine nucleotides. This concerns the conversion of SAICA-ribotide into aminoimidazole carboxamide ribotide and of adenylosuccinate into AMP (Fig. 1A) . A defect in the enzyme leads to accumulation of two usually undetectable compounds: SAICA-riboside, deriving from SAICA-ribotide; and succinyladenosine, deriving from adenylosuccinate. Both compounds can be detected readily in the urine of affected patients (Fig. 3C) . The 1 H-NMR spectrum of urine from two unrelated patients showed increased succinyladenosine (101 and 188 mol/mmol creatinine) and SAICA-riboside (162 and 214 mol/mmol creatinine). Recognition of SAICA-riboside in urine with 1 H-NMR spectroscopy may be hampered by the use of the antiepileptic drug Sabril ® (Vigabatrin), which produces a characteristic resonance profile that overlaps with the doublet resonance of SAICAriboside. In such a case, the compound can still be found in the spectrum through its singlet resonance. In the CSF of one of the patients, both SAICA-riboside and succinyladenosine were present in detectable amounts (198 and 216 mol/L, respectively).
Discussion
This study illustrates that many defects in purine and pyrimidine metabolism can be demonstrated with NMR spectroscopy of body fluids by the presence of abnormally high concentrations of specific metabolites. In an earlier study (12 ) , we have found unacceptable quantitative differences between HPLC, gas chromatography, and NMR results for uracil and thymine in urine samples. In Table 1 of the present study, we have compared HPLC and NMR results for several metabolites in urine that are of diagnostic importance in inborn errors of purine and pyrimidine metabolism. The sometimes very long time interval (up to 17 years) between the HPLC and the NMR measurements of course is a serious drawback of this approach. Table 1 is no more than a rough indication that for most metabolites the two techniques will give similar quantitative results. The larger discrepancies found for uracil, thymine, inosine, deoxyinosine, and deoxyguanosine in part are in line with the differences found in our earlier study (12 ) . The addition of uracil and thymine to urine samples gave excellent recovery values with NMR spectroscopy (12 ) . Currently we are preparing a separate validation study on NMR spectroscopy in urine samples where NMR technical aspects (length of relaxation time and other factors) and NMR performance (within-and between-run coefficients of variation, accu-racy, recovery, and correlation with other techniques) will be addressed. NMR spectroscopy measurements in urine samples were informative in all patients with inborn errors in pyrimidine metabolism. The 1 H-NMR spectra of urine samples from patients with dihydropyrimidine dehydrogenase and dihydropyrimidinase deficiency led directly to the diagnosis in all cases. Blood plasma and CSF were not investigated in dihydropyrimidine dehydrogenase deficiency; however, in dihydropyrimidinase deficiency, the diagnosis could be found with 1 H-NMR spectroscopy in both body fluids.
The absence of 3-ureidopropionic acid in the urine spectra of the patients with dihydropyrimidinase deficiency excluded the theoretical possibility of ␤-ureidopropionase deficiency. In this case, 1 H-NMR spectroscopy helped to pinpoint the enzyme defect. The defect in these patients was later confirmed at the enzyme level in a liver biopsy (10, 13, 14 ) . In future cases the use of 1 H-NMR spectroscopy of urine may be considered to confirm this particular enzyme defect at the metabolite level, omitting the liver biopsy and the confirmation at enzyme level and going directly to the DNA level for mutation analysis. Primary ␤-ureidopropionase deficiency has as yet not been found in humans. Secondary ␤-ureidopropionase deficiency has been reported in propionic acidemia (18 ) . Characteristic resonances of 3-ureidopropionic acid, one of the expected metabolites in this deficiency, can be observed with 1 H-NMR spectroscopy. In this way, the technique may help in diagnosing patients with as yet unknown inborn errors in purine or pyrimidine metabolism. Whether such resonances in a spectrum would be properly assigned depends only on the quality of the available model compound 1 H-NMR database. This is unlike the situation with conventional techniques, where special and often elaborate sample preparation in combination with thin-layer chromatography or HPLC is required to identify 3-ureidopropionic acid (19, 20 ) . To find as yet unknown inborn errors of metabolism with 1 H-NMR spectroscopy, the spectra of the model compounds of as many intermediates relevant in human metabolism as possible should be measured. This is a topic for further research.
In the patients with inborn errors of purine metabolism, 1 H-NMR spectroscopy of urine samples led to the diagnosis in all patients with PNP deficiency, xanthinuria, molybdenum cofactor deficiency, Lesch-Nyhan disease, ADA deficiency, and adenylosuccinate lyase deficiency. After allopurinol loading, the NMR spectra of the urine could discriminate between isolated XDH deficiency and combined XDH/AO deficiency through the presence of oxypurinol. Increased urinary xanthine and/or hypoxanthine formed the only characteristic in the 1 H-NMR spectrum in all samples from patients with XDH deficiency, molybdenum cofactor deficiency, and Lesch-Nyhan disease. It, therefore, was impossible to discriminate on the basis of the 1 H-NMR spectrum between these diagnoses without the use of other additional tests. In this respect it is a major disadvantage that uric acid is 1 H-NMR invisible and therefore cannot aid discrimination between these inborn errors of purine metabolism. APRT deficiency was the only enzyme defect in purine metabolism where no abnormality could be observed in the urinary 1 H-NMR spectrum. This is mainly because the characteristic metabolite 2,8-dihydroxyadenine is NMR invisible. The diagnosis of this patient would have been missed with 1 H-NMR spectroscopy of urine.
For some of the inborn errors in purine and pyrimidine metabolism, no 1 H-NMR spectra were recorded. Patients with myoadenylate deaminase deficiency and patients with pyrimidine-5Ј-nucleotidase deficiency have no characteristic metabolite profile in body fluids, although increased concentrations of pyrimidine nucleotides have been demonstrated in erythrocytes with 1 H-NMR spectroscopy of pyrimidine-5Ј-nucleotidase-deficient patients (11 ) . No samples were available of patients with orotic aciduria type I or II. These defects can be diagnosed on basis of the increased concentrations of orotic acid in urine. Orotic acid can be detected easily in the 1 H-NMR spectrum (singlet resonance at 6.22 ppm); therefore, these conditions cannot be missed with 1 H-NMR spectroscopy. In addition, no sample was available from patients with phosphoribosyl pyrophosphate synthase superactivity. Because hypoxanthine in urine is characteristically increased in this disease, we expect no difficulties in diagnosing this defect with 1 H-NMR spectroscopy.
In PNP deficiency, as yet unidentified resonances were demonstrated in all body fluid samples investigated. We never have observed these unknowns in Ͼ400 other body fluid samples (urine, plasma, and CSF) of controls or patients suspected to have inborn errors of metabolism. The resonances are likely to derive from several compounds. No other metabolites are known to occur in increased concentrations in body fluids of patients with PNP deficiency. Furthermore, there are to our knowledge no published reports indicating high concentrations of unknown metabolites in this disease. The urines of cases 1 and 2 were stored at Ϫ80°C for several years; therefore, storage artifacts should be considered. However, because some of these unknowns were also found in the serum of case 3, we consider this option unlikely because this sample was measured with NMR spectroscopy immediately after venipuncture. There were obvious differences in the NMR spectrum of the urine of cases 1 and 2. The concentrations of the four characteristic metabolites in this disease varied considerably between the two patients, and orotic aciduria was present only in case 1. Some of the unknown resonances were present in the urine of both patients, but again obvious concentration differences were present. Other unknowns were present in only one of the two patients. These data allow various explanations. Theoretically, the unknowns can be caused by medication, derive from the food, or may actually be a characteristic of the underlying enzyme deficiency. It would be conceivable that the patients may suffer from different metabolic diseases with partially overlapping metabolite profiles. However, this seems unlikely because the enzyme deficiency was shown convincingly in the patients (15, 16 ) . The occurrence of unknown resonances should be checked in urine samples from other patients with the disease. Because PNP deficiency is very rare, we would appreciate if urine, plasma, or CSF samples of affected patients would be made available for 1 H-NMR spectroscopy. In case our findings can be confirmed in other cases, additional NMR techniques (COSY, J-resolved, and long-range spectra) may help to solve the chemical structure of the unknown metabolites involved.
Orotic aciduria is a more or less controversial finding in PNP deficiency. It was described for the first time by Cohen et al. (21 ) in two unrelated patients with the disease and confirmed by van Gennip et al. (22 ) . Simmonds et al. (23 ) , however, could not confirm it with three independent methods. The mechanism of the orotic aciduria is unknown. It could be caused by the inhibition of orotate phosphoribosyltransferase by accumulating abnormal metabolites. The enzyme converts orotic acid and 5-phospho-␣-d-ribosyl-1-pyrophosphate into orotidine 5phosphate. It is known that inosine does not inhibit the enzyme in vitro. Perhaps one of the unknown metabolites found in our patients can cause this inhibitory effect. Another explanation for the presence of orotic acid is the higher availability of 5-phospho-␣-d-ribosyl-1-pyrophosphate, which leads to increased pyrimidine synthesis de novo and overflow at orotate phosphoribosyl transferase, the rate-limiting step in this pathway. NMR spectroscopy of urine of affected patients may uncover the role that the as yet unknown metabolites play in causing orotic aciduria in these patients.
The overall view on metabolism that 1 H-NMR spectroscopy provides is nicely illustrated by the various inborn errors of metabolism discussed here. The technique allows investigation of a body fluid sample from a patient clinically suspected to suffer from an inborn error of metabolism without focusing on a specific group of metabolites. Conventional techniques in metabolic screening provide information on specific groups of metabolites (amino acids, organic acids, polyols, and purines). Each of these requires specific methodology such as derivatization, extraction, chromatography steps, or detection techniques. The 1 H-NMR spectrum provides quantitative information on representatives from all of these metabolite groups without the use of derivatization or extraction steps. This is the major advantage of 1 H-NMR spectroscopy. Unfortunately, the spectrometer required for the technique is still very expensive. Another disadvantage is that the software required for the interpretation of the spectra cannot yet automatically recognize, assign, and quantify the many resonances present in a spectrum of complex matrices such as body fluids. Therefore, the interpretation of the spectra remains the most laborious part of the analysis. This aspect together with the high price of high-field strength spectrometers severely discourages the routine application of the technique in clinical chemistry.
